SrasV1, Main, Exploration, bibRecord, 004E41

Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus

Identifieur interne : 004E41 ( Main/Exploration ); précédent : 004E40; suivant : 004E42

Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus

Auteurs : Tania Ivens [Belgique] ; Christel Van Den Eynde [Belgique] ; Koen Van Acker [Belgique] ; Erik Nijs [Belgique] ; Géry Dams [Belgique] ; Eva Bettens [Belgique] ; Asa Ohagen [Belgique] ; Rudi Pauwels [Belgique] ; Kurt Hertogs [Belgique]

Source :

Journal of virological methods [ 0166-0934 ] ; 2005.

RBID : Pascal:05-0419019

Descripteurs français

KwdFr :
- Antiviraux (), Antiviraux (analyse), Antiviraux (métabolisme), Antiviraux (pharmacologie), Lignée cellulaire, Protéines à fluorescence verte, Réplication virale (), Virus du SRAS (), Virus du SRAS (physiologie), Évaluation préclinique de médicament.
MESH :
- analyse : Antiviraux.
- métabolisme : Antiviraux.
- pharmacologie : Antiviraux.
- physiologie : Virus du SRAS.
Pascal (Inist)
- Antiviraux, Coronavirus, Détection, Antiviral, Criblage haut débit, Lignée cellulaire, Microbiologie, Méthode, Protéines à fluorescence verte, Réplication virale, Virologie, Syndrome respiratoire aigu sévère, Virus du SRAS, Évaluation préclinique de médicament.

English descriptors

KwdEn :
- Antiviral, Antiviral Agents (analysis), Antiviral Agents (chemistry), Antiviral Agents (metabolism), Antiviral Agents (pharmacology), Cell Line, Coronavirus, Detection, Drug Evaluation, Preclinical, Green Fluorescent Proteins, High throughput screening, Method, Microbiology, SARS Virus (drug effects), SARS Virus (physiology), Severe acute respiratory syndrome, Virology, Virus Replication (drug effects).
MESH :
- chemical , analysis : Antiviral Agents.
- chemical , chemistry : Antiviral Agents.
- chemical , metabolism : Antiviral Agents.
- chemical , pharmacology : Antiviral Agents.
- drug effects : SARS Virus, Virus Replication.
- physiology : SARS Virus.
- Cell Line, Drug Evaluation, Preclinical, Green Fluorescent Proteins.

Abstract

The severity and global spread of the 2003 outbreak of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) highlighted the risks to human health posed by emerging viral diseases and emphasized the need for specific therapeutic agents instead of relying on existing broadly active antiviral compounds. The development of rapid screening assays is essential for antiviral drug discovery. Thus, a screening system for anti-SARS-CoV agents was developed, which evaluated compound potency, specificity and cytotoxicity at the initial screening phase. Cell lines were engineered to constitutively express an enhanced green fluorescent protein (EGFP) and used to detect (I) antiviral potency in SARS-CoV infection tests; (2) antiviral specificity in tests using the porcine coronavirus transmissible gastroenteritis virus (TGEV); and (3) cytotoxicity in the same assays without virus challenge. The assay system involves minimal manipulation after assay set-up, facilitates automated read-out and minimizes risks associated with hazardous viruses. The suitability of this assay system in drug discovery was demonstrated by screening of 3388 small molecule compounds. The results show that these assays can be applied to high-throughput screening for identification of inhibitors selectively active against SARS-CoV.

Affiliations:

Belgique

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus</title>
<author><name sortKey="Ivens, Tania" sort="Ivens, Tania" uniqKey="Ivens T" first="Tania" last="Ivens">Tania Ivens</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3</s1>
<s2>Mechelen 2800</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Mechelen 2800</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Van Den Eynde, Christel" sort="Van Den Eynde, Christel" uniqKey="Van Den Eynde C" first="Christel" last="Van Den Eynde">Christel Van Den Eynde</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3</s1>
<s2>Mechelen 2800</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Mechelen 2800</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Van Acker, Koen" sort="Van Acker, Koen" uniqKey="Van Acker K" first="Koen" last="Van Acker">Koen Van Acker</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3</s1>
<s2>Mechelen 2800</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Mechelen 2800</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Nijs, Erik" sort="Nijs, Erik" uniqKey="Nijs E" first="Erik" last="Nijs">Erik Nijs</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3</s1>
<s2>Mechelen 2800</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Mechelen 2800</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dams, Gery" sort="Dams, Gery" uniqKey="Dams G" first="Géry" last="Dams">Géry Dams</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3</s1>
<s2>Mechelen 2800</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Mechelen 2800</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bettens, Eva" sort="Bettens, Eva" uniqKey="Bettens E" first="Eva" last="Bettens">Eva Bettens</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3</s1>
<s2>Mechelen 2800</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Mechelen 2800</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ohagen, Asa" sort="Ohagen, Asa" uniqKey="Ohagen A" first="Asa" last="Ohagen">Asa Ohagen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3</s1>
<s2>Mechelen 2800</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Mechelen 2800</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pauwels, Rudi" sort="Pauwels, Rudi" uniqKey="Pauwels R" first="Rudi" last="Pauwels">Rudi Pauwels</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3</s1>
<s2>Mechelen 2800</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Mechelen 2800</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hertogs, Kurt" sort="Hertogs, Kurt" uniqKey="Hertogs K" first="Kurt" last="Hertogs">Kurt Hertogs</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3</s1>
<s2>Mechelen 2800</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Mechelen 2800</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0419019</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0419019 INIST</idno>
<idno type="RBID">Pascal:05-0419019</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000605</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000385</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000669</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000669</idno>
<idno type="wicri:doubleKey">0166-0934:2005:Ivens T:development:of:a</idno>
<idno type="wicri:Area/Main/Merge">005189</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15961169</idno>
<idno type="wicri:Area/PubMed/Corpus">002684</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002684</idno>
<idno type="wicri:Area/PubMed/Curation">002684</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002684</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002751</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002751</idno>
<idno type="wicri:Area/Ncbi/Merge">001010</idno>
<idno type="wicri:Area/Ncbi/Curation">001010</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001010</idno>
<idno type="wicri:doubleKey">0166-0934:2005:Ivens T:development:of:a</idno>
<idno type="wicri:Area/Main/Merge">004B74</idno>
<idno type="wicri:Area/Main/Curation">004E41</idno>
<idno type="wicri:Area/Main/Exploration">004E41</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus</title>
<author><name sortKey="Ivens, Tania" sort="Ivens, Tania" uniqKey="Ivens T" first="Tania" last="Ivens">Tania Ivens</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3</s1>
<s2>Mechelen 2800</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Mechelen 2800</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Van Den Eynde, Christel" sort="Van Den Eynde, Christel" uniqKey="Van Den Eynde C" first="Christel" last="Van Den Eynde">Christel Van Den Eynde</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3</s1>
<s2>Mechelen 2800</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Mechelen 2800</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Van Acker, Koen" sort="Van Acker, Koen" uniqKey="Van Acker K" first="Koen" last="Van Acker">Koen Van Acker</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3</s1>
<s2>Mechelen 2800</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Mechelen 2800</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Nijs, Erik" sort="Nijs, Erik" uniqKey="Nijs E" first="Erik" last="Nijs">Erik Nijs</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3</s1>
<s2>Mechelen 2800</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Mechelen 2800</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dams, Gery" sort="Dams, Gery" uniqKey="Dams G" first="Géry" last="Dams">Géry Dams</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3</s1>
<s2>Mechelen 2800</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Mechelen 2800</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bettens, Eva" sort="Bettens, Eva" uniqKey="Bettens E" first="Eva" last="Bettens">Eva Bettens</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3</s1>
<s2>Mechelen 2800</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Mechelen 2800</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ohagen, Asa" sort="Ohagen, Asa" uniqKey="Ohagen A" first="Asa" last="Ohagen">Asa Ohagen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3</s1>
<s2>Mechelen 2800</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Mechelen 2800</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pauwels, Rudi" sort="Pauwels, Rudi" uniqKey="Pauwels R" first="Rudi" last="Pauwels">Rudi Pauwels</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3</s1>
<s2>Mechelen 2800</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Mechelen 2800</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hertogs, Kurt" sort="Hertogs, Kurt" uniqKey="Hertogs K" first="Kurt" last="Hertogs">Kurt Hertogs</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3</s1>
<s2>Mechelen 2800</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Mechelen 2800</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of virological methods</title>
<title level="j" type="abbreviated">J. virol. methods</title>
<idno type="ISSN">0166-0934</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of virological methods</title>
<title level="j" type="abbreviated">J. virol. methods</title>
<idno type="ISSN">0166-0934</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term>
<term>Antiviral Agents (analysis)</term>
<term>Antiviral Agents (chemistry)</term>
<term>Antiviral Agents (metabolism)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Cell Line</term>
<term>Coronavirus</term>
<term>Detection</term>
<term>Drug Evaluation, Preclinical</term>
<term>Green Fluorescent Proteins</term>
<term>High throughput screening</term>
<term>Method</term>
<term>Microbiology</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (physiology)</term>
<term>Severe acute respiratory syndrome</term>
<term>Virology</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux ()</term>
<term>Antiviraux (analyse)</term>
<term>Antiviraux (métabolisme)</term>
<term>Antiviraux (pharmacologie)</term>
<term>Lignée cellulaire</term>
<term>Protéines à fluorescence verte</term>
<term>Réplication virale ()</term>
<term>Virus du SRAS ()</term>
<term>Virus du SRAS (physiologie)</term>
<term>Évaluation préclinique de médicament</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Cell Line</term>
<term>Drug Evaluation, Preclinical</term>
<term>Green Fluorescent Proteins</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antiviraux</term>
<term>Coronavirus</term>
<term>Détection</term>
<term>Antiviral</term>
<term>Criblage haut débit</term>
<term>Lignée cellulaire</term>
<term>Microbiologie</term>
<term>Méthode</term>
<term>Protéines à fluorescence verte</term>
<term>Réplication virale</term>
<term>Virologie</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Virus du SRAS</term>
<term>Évaluation préclinique de médicament</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The severity and global spread of the 2003 outbreak of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) highlighted the risks to human health posed by emerging viral diseases and emphasized the need for specific therapeutic agents instead of relying on existing broadly active antiviral compounds. The development of rapid screening assays is essential for antiviral drug discovery. Thus, a screening system for anti-SARS-CoV agents was developed, which evaluated compound potency, specificity and cytotoxicity at the initial screening phase. Cell lines were engineered to constitutively express an enhanced green fluorescent protein (EGFP) and used to detect (I) antiviral potency in SARS-CoV infection tests; (2) antiviral specificity in tests using the porcine coronavirus transmissible gastroenteritis virus (TGEV); and (3) cytotoxicity in the same assays without virus challenge. The assay system involves minimal manipulation after assay set-up, facilitates automated read-out and minimizes risks associated with hazardous viruses. The suitability of this assay system in drug discovery was demonstrated by screening of 3388 small molecule compounds. The results show that these assays can be applied to high-throughput screening for identification of inhibitors selectively active against SARS-CoV.</div>
</front>
</TEI>
<affiliations><list><country><li>Belgique</li>
</country>
</list>
<tree><country name="Belgique"><noRegion><name sortKey="Ivens, Tania" sort="Ivens, Tania" uniqKey="Ivens T" first="Tania" last="Ivens">Tania Ivens</name>
</noRegion>
<name sortKey="Bettens, Eva" sort="Bettens, Eva" uniqKey="Bettens E" first="Eva" last="Bettens">Eva Bettens</name>
<name sortKey="Dams, Gery" sort="Dams, Gery" uniqKey="Dams G" first="Géry" last="Dams">Géry Dams</name>
<name sortKey="Hertogs, Kurt" sort="Hertogs, Kurt" uniqKey="Hertogs K" first="Kurt" last="Hertogs">Kurt Hertogs</name>
<name sortKey="Nijs, Erik" sort="Nijs, Erik" uniqKey="Nijs E" first="Erik" last="Nijs">Erik Nijs</name>
<name sortKey="Ohagen, Asa" sort="Ohagen, Asa" uniqKey="Ohagen A" first="Asa" last="Ohagen">Asa Ohagen</name>
<name sortKey="Pauwels, Rudi" sort="Pauwels, Rudi" uniqKey="Pauwels R" first="Rudi" last="Pauwels">Rudi Pauwels</name>
<name sortKey="Van Acker, Koen" sort="Van Acker, Koen" uniqKey="Van Acker K" first="Koen" last="Van Acker">Koen Van Acker</name>
<name sortKey="Van Den Eynde, Christel" sort="Van Den Eynde, Christel" uniqKey="Van Den Eynde C" first="Christel" last="Van Den Eynde">Christel Van Den Eynde</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004E41 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004E41 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:05-0419019
   |texte=   Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

Serveur d'exploration SRAS

Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus

Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.